Clinical Trials Directory

Trials / Completed

CompletedNCT00668447

Soy and Isoflavones Effect on Bone

Soy Proteins and Isoflavones Impact Bone Mineral Density in Older Women

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
97 (actual)
Sponsor
United States Department of Agriculture (USDA) · Federal
Sex
Female
Age
65 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to test the effect of 1 year of added dietary soy protein and/or soy isoflavones on bone mineral density in late postmenopausal women.

Detailed description

Although soy foods contain several components (isoflavones and amino acids) that could potentially have positive effects on bone health, there are few long term, large, clinical trials using soy as a means of improving bone mineral density. The objective of this study is to provide daily soy protein and isoflavones to healthy older women in order to answer three major questions: 1. Does soy protein alone affect bone metabolism? 2. Do isoflavones, given with soy protein, affect bone metabolism? 3. What dose of isoflavones affects bone in older women? We hypothesize that soy protein will have a beneficial effect on bone in older women compared to control protein. Further, we hypothesize that there will be an additional benefit to bone in women who receive soy protein plus isoflavones (at both doses) compared to soy protein alone. Both control and soy proteins used in the study were isolates, meaning they were the highest concentration of protein (85-90% by weight) in order to minimize the volume of protein supplement that each woman was asked to ingest on a daily basis. The soy protein was an alcohol-washed, soy protein isolate containing 90% protein and negligible isoflavone (0.2 mg/g product). The control protein was a mix consisting of 50% protein from sodium caseinate, 25% protein from whey protein and 25% from egg white protein. The use of a mix of proteins as a control provides a more balanced level of amino acids, mimics the real life mix of proteins that humans typically consume, and avoids the unique characteristics of one source of protein. In order to maintain the dietary protein intake constant, the participant was counseled to decrease her intake of other sources of protein from primarily animal sources by approximately 3 ounces per day (the approximate equivalent of the protein powders). The isoflavones tablets each contained 57 mg of total isoflavone from primarily genistein, glycitein, and daidzein and their beta-glycosides.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTSoy Isolate20 grams of powder mixed in beverages or food daily for one year
DIETARY_SUPPLEMENTControl protein20 grams of powder mixed in beverages or food daily for one year
DIETARY_SUPPLEMENTNovasoy isoflavones3 tablets daily for one year
DIETARY_SUPPLEMENTPlacebo tablets3 tablets daily for one year

Timeline

Start date
2001-11-01
Primary completion
2005-06-01
Completion
2005-06-01
First posted
2008-04-29
Last updated
2008-04-29

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00668447. Inclusion in this directory is not an endorsement.